An international, expert-based, multispecialty Delphi consensus document on stroke risk stratification and the optimal management of patients with asymptomatic and symptomatic carotid stenosis
- PMID: 41005511
- DOI: 10.1016/j.jvs.2025.09.039
An international, expert-based, multispecialty Delphi consensus document on stroke risk stratification and the optimal management of patients with asymptomatic and symptomatic carotid stenosis
Abstract
Objective: The optimal management of patients with asymptomatic carotid stenosis (AsxCS) and symptomatic carotid stenosis (SxCS) is controversial and includes intensive medical management (ie, best medical therapy [BMT]) with or without an additional carotid revascularization procedure (ie, carotid endarterectomy [CEA], transfemoral carotid artery stenting [TFCAS] or transcarotid artery revascularization [TCAR]). The aim of this international, expert-based, multispecialty Delphi consensus document was to reconcile the conflicting views regarding the optimal management of AsxCS and SxCS patients.
Methods: A three-round Delphi consensus process was performed including 63 experts from Europe (n = 37) and the United States (n = 26). A total of six different clinical scenarios were identified involving patients with either AsxCS or SxCS. For each scenario, five treatment options were available: (i) BMT alone, (ii) BMT plus CEA, (iii) BMT plus TFCAS, (iv) BMT plus TCAR, and (v) BMT plus CEA/TFCAS/TCAR. Differences in treatment preferences between US and European participants were assessed using Fisher's exact test, and odds ratios were used to quantify the magnitude and direction of association. Consensus was achieved when >70% of the Delphi consensus participants agreed on a therapeutic approach.
Results: Most participants concurred that BMT alone is not adequate for the management of a 70-year-old fit male or female patient with 80% to 99% AsxCS (52/63 [82.5%] and 45/63 [71.5%], respectively). In contrast, most panelists would opt for BMT alone for an 80-year-old male AsxCS patient with several comorbidities (48/63 [76.2%]). The majority of participants would opt for BMT plus a carotid revascularization procedure for an 80-year-old male SxCS patient with a recent ipsilateral cerebrovascular event, an ipsilateral 70% to 99% SxCS, and a 5-year predicted risk of ipsilateral ischemic event of 10% (54/63 [85.7%]), 15% (59/63 [93.6%]), or 20% (63/63 [100%]). The opinion of US-based participants varied from that of Europe-based respondents in some scenarios.
Conclusions: The panel agreed that BMT alone is insufficient for most patients with SxCS, and that select subgroups of AsxCS patients may also benefit from revascularization, especially when high-risk features are present. Patients should be stratified according to their predicted stroke risk, as well as their individual clinical, anatomical, and imaging features and should be treated accordingly.
Keywords: Asymptomatic carotid stenosis; Best medical therapy; Carotid artery stenting; Carotid endarterectomy; Stroke risk; Symptomatic carotid stenosis; Transcarotid artery revascularization.
Copyright © 2025 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures M.C.S. has a consultant agreement with Boston Scientific. M.B.M. is a consultant to Cordis and Bard. P.A.S. is a consultant to Surmodics, Medtronic, Boston Scientific, Cagent, Acotec, Abbott, Endologix, Shockwave, Healthcare Inroads, Inari, and BD. M.K.E. is a paid consultant for W. L. Gore & Associates and Silkroad Medical (Boston Scientific). M.D. is a consultant/speaker for Boston Scientific Vascular and Medtronic Aortic. M.L.S. is PI for Medtronic, Boston Scientific and Shape clinical trials. He also does research with Cook, Terumo, and W. L. Gore & Associates. G.R. is the chair of the Interventional Management Committee of CREST-2. He is also InspireMD Inc. Director and stock holder. P.M. is co-principal investigator in the CGUARDIANS FDA-IDE and in the CARENET Trial and is principal investigator in the PARADIGM/PARADIGM-Extend, FLOWGUARD, OPTIMA, TOPGUARD, and SAFEGUARD-STROKE Carotid trials. He is a voting member of the ESC WG CARE, a member of the EuroPCR VITAL and EuroPCR Programme Producer and Session Quality Evaluator, and is a co-director of the ICCA/Stroke and Polish Cardiac Society Board Representative for Stroke and Vascular Interventions. He has proctored and/or consulted for Abbott Vascular, Balton, Gore, InspireMD, Medtronic, and Penumbra, and serves on the steering committee of the Medtronic SHIELD Study. S.P.L. is a consultant for BD, Boston Scientific, Contego Medical, Cordis, Endologix, Inspire MD, Medtronic, Rapid Medical, Shockwave, Penumbra, Vivasure, and Nectero. He has stock options in Inspire MD, Reva Medical, and Centerline Biomedical. He is a board member for VIVA Physicians. He has performed Research Studies for Abbott, Endologix, Surmodics, W. L. Gore & Associates, Terumo Aortic, NIH, Boston Scientific, Merit, Contego Medical, Inspire MD, Reva Medical, Penumbra, Medalliance, and Nectero.
LinkOut - more resources
Full Text Sources
Medical
